Compare Amylx Pharmaceuticals Inc (AMLX) vs Simon Property Group Inc (SPG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Simon Property Group Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Simon Property Group Inc trades at $218 (market cap $70.94B). The key difference: Simon Property Group Inc is far larger — about 35.8× Amylx Pharmaceuticals Inc's market cap, and Simon Property Group Inc pays a 4.02% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SPG | |
|---|---|---|
Market Cap | $1.98B | $70.94B |
Sector | Health | Real Estate |
52-Week High | $18.70 | $227.56 |
52-Week Low | $7.64 | $159.93 |
Enterprise Value | $1.70B | $99.42B |
Dividend Yield | — | 4.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Simon Property Group (SPG) trades at $218.77, down 0.43% on the day, with a bullish technical signal from moving averages. The REIT shows strong profitability with a 70.59% net income margin and has beaten earnings estimates in three consecutive quarters. Recent news highlights robust Q1 2026 results and a dividend payout of $2.25 for H1-26.
Outlook remains positive due to strong leasing and redevelopment, but risks include high debt levels and e-commerce competition. Analyst consensus is mixed with a $214.40 price target, slightly below current levels, suggesting cautious optimism amid solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
